Glycostem's NK Cell Product oNKordĀ® received Orphan drug designation for AML

ODD for NK Cell Product oNKordĀ® to treat AML

NK_Figuren3.jpg

18 November 2014, EMA/COMP/641491/2014

During their plenary meeting on 11-13 November 2014 the Committee for Orphan Medicinal Products (COMP) has adopted at the first discussion a positive opinion recommending Glycostem's NK Cell Product* for designation as orphan medicinal product to the European Commission (EC).

*) Allogeneic ex vivo-generated natural killer cells from CD34+ umbilical cord blood progenitor cells for treatment of acute myeloid leukaemia